Faruqi & Faruqi, LLP is investigating the claims on behalf of investors AstraZeneca ulaganjem.com

Faruqi and Faruqi, Litigation Partner for LLP James (Josh) Wilson He encourages investors who have suffered losses in AstraZenecato contact him directly to discuss their options

If you bought or acquired securities in AstraZeneca (NASDAQ 🙂 Between February 23, 2022 and December 17, 2024. And you’d like to discuss your legal rights, call your partner Faruqi and Faruqi Josh Wilson direct on 877-247-4292 or 212-983-9330 (Ext. 1310).

[You may also click here for additional information]

New York, New York – (Newsfile Corp. – January 26, 2025) – Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against AstraZeneca PLC (LON 🙂 (“AstraZeneca” or the “Company” “) (NASDAQ: AZN) and reminds investors to February 21, 2025 seek the role of lead plaintiff in a federal securities class action filed against the company.

Faruqi and Faruqi is a leading national law firm with offices in New York, Pennsylvania, California and Georgia. The company has taken out hundreds of millions of dollars for investors since it was founded in 1995. See www.faruqilaw.com.

As detailed below, the complaint alleges that the company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that (1) AstraZeneca engaged in insurance fraud in China; (2) as a result, AstraZeneca faced increased legal exposure in China, which ultimately resulted in Chinese law enforcement authorities arresting AstraZeneca in the custody of Chinese authorities; (3) as a result, AstraZeneca underestimated its legal risks; (4) the foregoing, once disclosed, could materially harm AstraZeneca’s business activities in China; and (5) as a result, the defendant’s statements about its business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

On October 30, 2024, AstraZeneca announced that Leon Wang, executive vice president of International and AstraZeneca China, was “cooperating with the ongoing investigation by Chinese authorities.”

On this news, AstraZeneca American Depositary Shares (“ADS”) fell 3.1% on October 30, 2024.

Then on November 5, 2024, Yicai Global published an article titled “AstraZeneca Insurance Fraud Involves Dozens of Senior Executives in China, Source Says.” This article stated that “[d]Dozens of senior AstraZeneca executives have been implicated in an ongoing insurance fraud case since last week, according to a person familiar with the matter. “Furthermore, it is stated that the “said[o]In the past three years, insurance fraud cases involving AstraZeneca have emerged in Shenzhen, as well as the provinces of Fujian and Jiangxi. [. . .] These cases represent the biggest insurance fraud in the state pharmaceutical sector in years, said a person familiar with the matter. “

In this news, AstraZeneca ADSS fell an additional 7.2% on November 5, 2024.

A court-appointed lead plaintiff is the investor with the greatest financial interest in the relief sought by the class that is adequate and typical of class members directing and overseeing litigation on behalf of the purported class. Each putative class member can move the Court to serve as lead plaintiff through counsel of their choosing, or they can choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as lead plaintiff or not.

Faruqi and Faruqi, LLP also encourages anyone with information about AstraZeneca’s conduct to contact the company, including whistleblowers, former employees, shareholders and others.

Advertising of lawyers. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Past results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your specific case. All communications will be treated confidentially.

To view the original version of this release, please visit https://www.newsfilecorp.com/release/238371